Publications 2024

Egeland EV, Seip K, Skourti E, Øy GF, Pettersen SJ, Pandya AD, Dahle MA, Haugen MH, Kristian A, Nakken S, Engebraaten O, Mælandsmo GM, Prasmickaite L (2024)
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy
Br J Cancer, 131 (10), 1656-1667
DOI 10.1038/s41416-024-02875-5, PubMed 39390250

Fleischer T, Haugen MH, Ankill J, Silwal-Pandit L, Børresen-Dale AL, Hedenfalk I, Hatschek T, Tost J, Engebraaten O, Kristensen VN (2024)
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
Mol Oncol, 18 (8), 2042-2059
DOI 10.1002/1878-0261.13656, PubMed 38671580

Ohnstad HO, Blix ES, Akslen LA, Gilje B, Raj SX, Skjerven H, Borgen E, Janssen EAM, Mortensen E, Brekke MB, Falk RS, Schlichting E, Boge B, Songe-Møller S, Olsson P, Heie A, Mannsåker B, Vestlid MA, Kursetgjerde T, Gravdehaug B, Suhrke P, Sanchez E, Bublevic J, Røe OD, Geitvik GA et al. (2024)
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)
ESMO Open, 9 (6), 103475
DOI 10.1016/j.esmoop.2024.103475, PubMed 38838499

Publications 2023

Haugen MH, von der Lippe Gythfeldt H, Egeland EV, Svartdal Normann L, Pandya AD, Vedin LL, Juell S, Tenstad E, Øy GF, Kristian A, Marangoni E, Sørlie T, Steffensen K, Maelandsmo GM, Engebraaten O (2023)
Liver X receptors induce antiproliferative effects in basal-like breast cancer
Mol Oncol, 17 (10), 2041-2055
DOI 10.1002/1878-0261.13476, PubMed 37341140

Mo T, Brandal SHB, Geier OM, Engebråten O, Nilsen LB, Kristensen VN, Hole KH, Hompland T, Fleischer T, Seierstad T (2023)
MRI Assessment of Changes in Tumor Vascularization during Neoadjuvant Anti-Angiogenic Treatment in Locally Advanced Breast Cancer Patients
Cancers (Basel), 15 (18)
DOI 10.3390/cancers15184662, PubMed 37760629

Normann LS, Haugen MH, Hongisto V, Aure MR, Leivonen SK, Kristensen VN, Tahiri A, Engebraaten O, Sahlberg KK, Mælandsmo GM (2023)
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
PLoS One, 18 (1), e0280507
DOI 10.1371/journal.pone.0280507, PubMed 36706086

Pettersen S, Øy GF, Egeland EV, Juell S, Engebråten O, Mælandsmo GM, Prasmickaite L (2023)
Breast cancer patient-derived explant cultures recapitulate in vivo drug responses
Front Oncol, 13, 1040665
DOI 10.3389/fonc.2023.1040665, PubMed 36910663

Publications 2022

Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2022)
Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
J Control Release, 349, 1
DOI 10.1016/j.jconrel.2022.06.040, PubMed 35792388

Mo T, Brandal SHB, Köhn-Luque A, Engebraaten O, Kristensen VN, Fleischer T, Hompland T, Seierstad T (2022)
Quantification of Tumor Hypoxia through Unsupervised Modelling of Consumption and Supply Hypoxia MR Imaging in Breast Cancer
Cancers (Basel), 14 (5)
DOI 10.3390/cancers14051326, PubMed 35267636

Publications 2021

Barkovskaya A, Goodwin CM, Seip K, Hilmarsdottir B, Pettersen S, Stalnecker C, Engebraaten O, Briem E, Der CJ, Moestue SA, Gudjonsson T, Maelandsmo GM, Prasmickaite L (2021)
Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen
Mol Oncol, 15 (8), 2026-2045
DOI 10.1002/1878-0261.12951, PubMed 33759347

Engebraaten O, Yau C, Berg K, Borgen E, Garred Ø, Berstad MEB, Fremstedal ASV, DeMichele A, Veer LV', Esserman L, Weyergang A (2021)
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
Nat Commun, 12 (1), 6427
DOI 10.1038/s41467-021-26018-z, PubMed 34741021

Erdélyi K, Ditrói T, Johansson HJ, Czikora Á, Balog N, Silwal-Pandit L, Ida T, Olasz J, Hajdú D, Mátrai Z, Csuka O, Uchida K, Tóvári J, Engebraten O, Akaike T, Børresen Dale AL, Kásler M, Lehtiö J, Nagy P (2021)
Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation
Proc Natl Acad Sci U S A, 118 (45)
DOI 10.1073/pnas.2100050118, PubMed 34737229

Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O (2021)
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
JCO Precis Oncol, 5
DOI 10.1200/PO.20.00086, PubMed 34036235

Krüger K, Silwal-Pandit L, Wik E, Straume O, Stefansson IM, Borgen E, Garred Ø, Naume B, Engebraaten O, Akslen LA (2021)
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Sci Rep, 11 (1), 3388
DOI 10.1038/s41598-021-81914-0, PubMed 33564016

Pandya AD, Iversen TG, Moestue S, Grinde MT, Mørch Ý, Snipstad S, Åslund AKO, Øy GF, Kildal W, Engebråten O, Sandvig K, Skotland T, Mælandsmo GM (2021)
Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft
Nanomaterials (Basel), 11 (5)
DOI 10.3390/nano11051140, PubMed 33924869

Publications 2020

Pladsen AV, Nilsen G, Rueda OM, Aure MR, Borgan Ø, Liestøl K, Vitelli V, Frigessi A, Langerød A, Mathelier A, OSBREAC, Engebråten O, Kristensen V, Wedge DC, Van Loo P, Caldas C, Børresen-Dale AL, Russnes HG, Lingjærde OC (2020)
DNA copy number motifs are strong and independent predictors of survival in breast cancer
Commun Biol, 3 (1), 153
DOI 10.1038/s42003-020-0884-6, PubMed 32242091

von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred Ø, Skjerven H, Schlichting E, Lundgren S, Wist E, Naume B, Kristensen V, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2020)
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Int J Cancer, 147 (9), 2515-2525
DOI 10.1002/ijc.33108, PubMed 32488909

Publications 2019

Andersson Y, Inderberg EM, Kvalheim G, Herud TM, Engebraaten O, Flatmark K, Dueland S, Fodstad Ø (2019)
Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
Acta Oncol, 59 (4), 404-409
DOI 10.1080/0284186X.2019.1704864, PubMed 31876430

Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201

Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562

Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X (2019)
Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
Int J Cancer, 146 (1), 223-235
DOI 10.1002/ijc.32638, PubMed 31444972

Publications 2018

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W et al. (2018)
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
J Natl Cancer Inst, 110 (6), 560-567
DOI 10.1093/jnci/djy018, PubMed 29659933

Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2018)
Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
J Control Release, 293, 183-192
DOI 10.1016/j.jconrel.2018.11.029, PubMed 30529259

Höglander EK, Nord S, Wedge DC, Lingjærde OC, Silwal-Pandit L, Gythfeldt HV, Vollan HKM, Fleischer T, Krohn M, Schlitchting E, Borgen E, Garred Ø, Holmen MM, Wist E, Naume B, Van Loo P, Børresen-Dale AL, Engebraaten O, Kristensen V (2018)
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
Genome Med, 10 (1), 92
DOI 10.1186/s13073-018-0601-y, PubMed 30497530

Jabeen S, Espinoza JA, Torland LA, Zucknick M, Kumar S, Haakensen VD, Lüders T, Engebraaten O, Børresen-Dale AL, Kyte JA, Gromov P, Naume B, Kristensen V, Gromova I, Tekpli X (2018)
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
Oncoimmunology, 8 (2), e1537691
DOI 10.1080/2162402X.2018.1537691, PubMed 30713794

Jabeen S, Zucknick M, Nome M, Dannenfelser R, Fleischer T, Kumar S, Lüders T, von der Lippe Gythfeldt H, Troyanskaya O, Kyte JA, Børresen-Dale AL, Naume B, Tekpli X, Engebraaten O, Kristensen V (2018)
Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
Oncoimmunology, 7 (11), e1457598
DOI 10.1080/2162402X.2018.1457598, PubMed 30377556

Prasmickaite L, Tenstad EM, Pettersen S, Jabeen S, Egeland EV, Nord S, Pandya A, Haugen MH, Kristensen VN, Børresen-Dale AL, Oslo Breast Cancer Research Consortium (OSBREAC), Engebråten O, Maelandsmo GM (2018)
Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4
Mol Oncol, 12 (9), 1540-1558
DOI 10.1002/1878-0261.12319, PubMed 29741811

Seip K, Jørgensen K, Haselager MV, Albrecht M, Haugen MH, Egeland EV, Lucarelli P, Engebraaten O, Sauter T, Mælandsmo GM, Prasmickaite L (2018)
Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment
Cancer Lett, 439, 1-13
DOI 10.1016/j.canlet.2018.09.023, PubMed 30240588

Publications 2017

Euceda LR, Haukaas TH, Giskeodegard GF, Vettukattil R, Engel J, Silwal-Pandit L, Lundgren S, Borgen E, Garred O, Postma G, Buydens LMC, Borresen-Dale AL, Engebraaten O, Bathen TF (2017)
Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
Metabolomics, 13 (4), 37
DOI 10.1007/s11306-017-1168-0

Kristian A, Holtedahl JE, Torheim T, Futsaether C, Hernes E, Engebraaten O, Mælandsmo GM, Malinen E (2017)
Dynamic 2-Deoxy-2-[¹⁸F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts
Mol Imaging Biol, 19 (2), 271-279
DOI 10.1007/s11307-016-0998-x, PubMed 27541026

Saldova R, Haakensen VD, Rødland E, Walsh I, Stöckmann H, Engebraaten O, Børresen-Dale AL, Rudd PM (2017)
Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up
Mol Oncol, 11 (10), 1361-1379
DOI 10.1002/1878-0261.12105, PubMed 28657165

Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL et al. (2017)
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Clin Cancer Res, 23 (16), 4662-4670
DOI 10.1158/1078-0432.CCR-17-0160, PubMed 28487444

Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, Sønstevold T, Engebraaten O, Flatmark K, Mælandsmo GM, Skotland T, Sandvig K (2017)
Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide
Oncotarget, 8 (44), 76921-76934
DOI 10.18632/oncotarget.20217, PubMed 29100358

Publications 2016

Kim E, Tunset HM, Cebulla J, Vettukattil R, Helgesen H, Feuerherm AJ, Engebråten O, Mælandsmo GM, Johansen B, Moestue SA (2016)
Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model
BMC Cancer, 16, 191
DOI 10.1186/s12885-016-2225-1, PubMed 26951085

Reinertsen KV, Engebraaten O, Loge JH, Cvancarova M, Naume B, Wist E, Edvardsen H, Wille E, Bjøro T, Kiserud CE (2016)
Fatigue During and After Breast Cancer Therapy-A Prospective Study
J Pain Symptom Manage, 53 (3), 551-560
DOI 10.1016/j.jpainsymman.2016.09.011, PubMed 28042070

Publications 2015

Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S (2015)
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
Br J Cancer, 113 (11), 1548-55
DOI 10.1038/bjc.2015.380, PubMed 26554649

Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, Børresen-Dale AL, Neilsen PM, Prives C (2015)
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells
Genes Dev, 29 (12), 1298-315
DOI 10.1101/gad.263202.115, PubMed 26080815

Publications 2014

Bagherifam S, Skjeldal FM, Griffiths G, Mælandsmo GM, Engebråten O, Nyström B, Hasirci V, Hasirci N (2014)
pH-responsive nano carriers for doxorubicin delivery
Pharm Res, 32 (4), 1249-63
DOI 10.1007/s11095-014-1530-0, PubMed 25288014

Esmaeili M, Moestue SA, Hamans BC, Veltien A, Kristian A, Engebråten O, Maelandsmo GM, Gribbestad IS, Bathen TF, Heerschap A (2014)
In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts
J Magn Reson Imaging, 41 (3), 601-9
DOI 10.1002/jmri.24588, PubMed 24532410

Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Børresen-Dale AL, Mælandsmo GM, Engebraaten O, Sørlie T, Marangoni E, Gribbestad IS (2014)
Interplay of choline metabolites and genes in patient-derived breast cancer xenografts
Breast Cancer Res, 16 (1), R5
DOI 10.1186/bcr3597, PubMed 24447408

Kristian A, Riss P, Qu H, Milde M, Schoultz BW, Engebraaten O, Mælandsmo GM, Malinen E (2014)
Positron emission tomography and pharmacokinetics of 2-[18F]-fluoroethyl choline for metabolic studies in breast cancer xenografts
Acta Oncol, 53 (8), 1086-92
DOI 10.3109/0284186X.2014.934398, PubMed 25017377

Nilsen LB, Fangberget A, Geier OM, Engebraaten O, Borgen E, Olsen DR, Seierstad T (2014)
Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis
J Magn Reson Imaging, 40 (6), 1382-91
DOI 10.1002/jmri.24502, PubMed 24470360

Skrbo N, Hjortland GO, Kristian A, Holm R, Nord S, Prasmickaite L, Engebraaten O, Mælandsmo GM, Sørlie T, Andersen K (2014)
Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft
PLoS One, 9 (11), e113278
DOI 10.1371/journal.pone.0113278, PubMed 25419568

Publications 2013

Engebraaten O, Vollan HKM, Børresen-Dale AL (2013)
Triple-negative breast cancer and the need for new therapeutic targets
Am J Pathol, 183 (4), 1064-1074
DOI 10.1016/j.ajpath.2013.05.033, PubMed 23920327

Esmaeili M, Bathen TF, Engebråten O, Mælandsmo GM, Gribbestad IS, Moestue SA (2013)
Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts
Magn Reson Med, 71 (6), 1973-81
DOI 10.1002/mrm.24869, PubMed 23878023

Kristian A, Nilsen LB, Røe K, Revheim ME, Engebråten O, Mælandsmo GM, Holm R, Malinen E, Seierstad T (2013)
Dynamic (18) F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts
Nucl Med Mol Imaging, 47 (3), 173-80
DOI 10.1007/s13139-013-0211-y, PubMed 24900104

Kristian A, Revheim ME, Qu H, Mælandsmo GM, Engebråten O, Seierstad T, Malinen E (2013)
Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts
Acta Oncol, 52 (7), 1566-72
DOI 10.3109/0284186X.2013.813634, PubMed 23984812

Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, Engebraaten O (2013)
Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations
Clin Cancer Res, 20 (2), 404-12
DOI 10.1158/1078-0432.CCR-13-1865, PubMed 24192926

Moestue SA, Dam CG, Gorad SS, Kristian A, Bofin A, Mælandsmo GM, Engebråten O, Gribbestad IS, Bjørkøy G (2013)
Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer
Breast Cancer Res, 15 (1), R16
DOI 10.1186/bcr3391, PubMed 23448424

Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Mælandsmo GM, Akslen LA, Gribbestad IS (2013)
Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts
J Magn Reson Imaging, 38 (5), 1043-53
DOI 10.1002/jmri.24079, PubMed 23908122

Publications 2012

Borgan E, Lindholm EM, Moestue S, Mælandsmo GM, Lingjærde OC, Gribbestad IS, Børresen-Dale AL, Engebraaten O, Sørlie T (2012)
Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts
Mol Oncol, 7 (1), 130-42
DOI 10.1016/j.molonc.2012.10.005, PubMed 23142657

Engebraaten O, Edvardsen H, Løkkevik E, Naume B, Kristensen V, Ottestad L, Natarajan V (2012)
Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
ISRN Oncol, 2012, 176789
DOI 10.5402/2012/176789, PubMed 22666610

Engesæter B, Engebraaten O, Flørenes VA, Mælandsmo GM (2012)
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma
PLoS One, 7 (9), e45492
DOI 10.1371/journal.pone.0045492, PubMed 23029050

Lindholm EM, Kristian A, Nalwoga H, Krüger K, Nygård S, Akslen LA, Mælandsmo GM, Engebraaten O (2012)
Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts
Mol Oncol, 6 (4), 418-27
DOI 10.1016/j.molonc.2012.03.006, PubMed 22521242

Publications 2011

Engesæter BO, Sathermugathevan M, Hellenes T, Engebråten O, Holm R, Flørenes VA, Mælandsmo GM (2011)
Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells
Cancer Biol Ther, 12 (1), 47-58
DOI 10.4161/cbt.12.1.15714, PubMed 21508672

Grinde MT, Moestue SA, Borgan E, Risa Ø, Engebraaten O, Gribbestad IS (2011)
13C high-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns
NMR Biomed, 24 (10), 1243-52
DOI 10.1002/nbm.1683, PubMed 21462378

Huuse EM, Moestue SA, Lindholm EM, Bathen TF, Nalwoga H, Krüger K, Bofin A, Maelandsmo GM, Akslen LA, Engebraaten O, Gribbestad IS (2011)
In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts
J Magn Reson Imaging, 35 (5), 1098-107
DOI 10.1002/jmri.23507, PubMed 22170753

Moestue SA, Engebraaten O, Gribbestad IS (2011)
Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy
Mol Oncol, 5 (3), 224-41
DOI 10.1016/j.molonc.2011.04.001, PubMed 21536506

Publications 2010

Fangberget A, Nilsen LB, Hole KH, Holmen MM, Engebraaten O, Naume B, Smith HJ, Olsen DR, Seierstad T (2010)
Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging
Eur Radiol, 21 (6), 1188-99
DOI 10.1007/s00330-010-2020-3, PubMed 21127880

Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Børresen-Dale AL, Engebraaten O, Maelandsmo GM, Gribbestad IS (2010)
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models
BMC Cancer, 10, 433
DOI 10.1186/1471-2407-10-433, PubMed 20716336

Prasmickaite L, Skrbo N, Høifødt HK, Suo Z, Engebråten O, Gullestad HP, Aamdal S, Fodstad Ø, Maelandsmo GM (2010)
Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells
Pigment Cell Melanoma Res, 23 (3), 449-51
DOI 10.1111/j.1755-148X.2010.00690.x, PubMed 20236249

Publications 2009

Andersson Y, Engebraaten O, Fodstad Ø (2009)
Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
Br J Cancer, 101 (8), 1307-15
DOI 10.1038/sj.bjc.6605312, PubMed 19773757

Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O (2009)
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
Mol Oncol, 3 (5-6), 469-82
DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161

Engebraaten O, Trikha M, Juell S, Garman-Vik S, Fodstad Ø (2009)
Inhibition of in vivo tumour growth by the blocking of host alpha(v)beta3 and alphaII(b)beta3 integrins
Anticancer Res, 29 (1), 131-7
PubMed 19331142

Publications 2007

Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O (2007)
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines
J Gene Med, 9 (6), 440-51
DOI 10.1002/jgm.1036, PubMed 17410615

Publications 2006

Engesaeter BØ, Bonsted A, Lillehammer T, Engebraaten O, Berg K, Maelandsmo GM (2006)
Photochemically mediated delivery of AdhCMV-TRAIL augments the TRAIL-induced apoptosis in colorectal cancer cell lines
Cancer Biol Ther, 5 (11), 1511-20
DOI 10.4161/cbt.5.11.3301, PubMed 17012835

Engesaeter BØ, Tveito S, Bonsted A, Engebraaten O, Berg K, Maelandsmo GM (2006)
Photochemical treatment with endosomally localized photosensitizers enhances the number of adenoviruses in the nucleus
J Gene Med, 8 (6), 707-18
DOI 10.1002/jgm.902, PubMed 16518880

Publications 2005

Engesaeter BØ, Bonsted A, Berg K, Høgset A, Engebråten O, Fodstad Ø, Curiel DT, Maelandsmo GM (2005)
PCI-enhanced adenoviral transduction employs the known uptake mechanism of adenoviral particles
Cancer Gene Ther, 12 (5), 439-48
DOI 10.1038/sj.cgt.7700808, PubMed 15678152

Lillehammer T, Tveito S, Engesaeter BO, Fodstad O, Maelandsmo GM, Engebraaten O (2005)
Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers
Cancer Gene Ther, 12 (11), 864-72
DOI 10.1038/sj.cgt.7700852, PubMed 15891771

Publications 2004

Hjortland GO, Garman-Vik SS, Juell S, Olsen OE, Hirschberg H, Fodstad O, Engebraaten O (2004)
Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme
J Neurosurg, 100 (2), 320-7
DOI 10.3171/jns.2004.100.2.0320, PubMed 15086240

Hjortland GO, Lillehammer T, Somme S, Wang J, Halvorsen T, Juell S, Hirschberg H, Fodstad Ø, Engebraaten O (2004)
Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells
Exp Cell Res, 294 (1), 130-9
DOI 10.1016/j.yexcr.2003.10.013, PubMed 14980508

Publications 2003

Hjortland GO, Bjørnland K, Pettersen S, Garman-Vik SS, Emilsen E, Nesland JM, Fodstad O, Engebraaten O (2003)
Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1
Clin Exp Metastasis, 20 (4), 301-9
DOI 10.1023/a:1024040718238, PubMed 12856717

Publications 2002

Engebraaten O, Hjortland GO, Juell S, Hirschberg H, Fodstad O (2002)
Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals
Int J Cancer, 97 (6), 846-52
DOI 10.1002/ijc.10137, PubMed 11857366

Friesen SA, Hjortland GO, Madsen SJ, Hirschberg H, Engebraten O, Nesland JM, Peng Q (2002)
5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review)
Int J Oncol, 21 (3), 577-82
PubMed 12168102

Mahesparan R, Read TA, Lund-Johansen M, Skaftnesmo KO, Bjerkvig R, Engebraaten O (2002)
Expression of extracellular matrix components in a highly infiltrative in vivo glioma model
Acta Neuropathol, 105 (1), 49-57
DOI 10.1007/s00401-002-0610-0, PubMed 12471461

Ree AH, Engebraaten O, Hovig E, Fodstad Ø (2002)
Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells
Int J Cancer, 97 (1), 28-33
DOI 10.1002/ijc.1564, PubMed 11774240

Publications 2001

Laerum OD, Nygaar SJ, Steine S, Mørk SJ, Engebraaten O, Peraud A, Kleihues P, Ohgaki H (2001)
Invasiveness in vitro and biological markers in human primary glioblastomas
J Neurooncol, 54 (1), 1-8
DOI 10.1023/a:1012565503958, PubMed 11763417

Publications 2000

Engebraaten O, Sivam G, Juell S, Fodstad O (2000)
Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats
Int J Cancer, 88 (6), 970-6
DOI 10.1002/1097-0215(20001215)88:6<970::aid-ijc21>3.0.co;2-q, PubMed 11093823

Visted T, Thorsen J, Thorsen F, Read TA, Ulvestad E, Engebraaten O, Sorensen D, Ylä-Herttuala S, Tyynela K, Rucklidge G, Edvardsen K, Bjerkvig R, Lund-Johansen M (2000)
lacZ-neoR transfected glioma cells in syngeneic rats: growth pattern and characterization of the host immune response against cells transplanted inside and outside the CNS
Int J Cancer, 85 (2), 228-35
DOI 10.1002/(SICI)1097-0215(20000115)85:2<228::AID-IJC13>3.0.CO;2-9, PubMed 10629082

Publications 1999

Engebraaten O, Fodstad O (1999)
Site-specific experimental metastasis patterns of two human breast cancer cell lines in nude rats
Int J Cancer, 82 (2), 219-25
DOI 10.1002/(sici)1097-0215(19990719)82:2<219::aid-ijc12>3.0.co;2-#, PubMed 10389756

Engebraaten O, Hjortland GO, Hirschberg H, Fodstad O (1999)
Growth of precultured human glioma specimens in nude rat brain
J Neurosurg, 90 (1), 125-32
DOI 10.3171/jns.1999.90.1.0125, PubMed 10413165

Ree AH, Tvermyr M, Engebraaten O, Rooman M, Røsok O, Hovig E, Meza-Zepeda LA, Bruland OS, Fodstad O (1999)
Expression of a novel factor in human breast cancer cells with metastatic potential
Cancer Res, 59 (18), 4675-80
PubMed 10493524

Publications 1998

Wyller TB, Engebråten O (1998)
[Use of antipsychotic drugs in a long-term care institution. Experiences with implementing clinical guidelines]
Tidsskr Nor Laegeforen, 118 (14), 2144-7
PubMed 9656807

Publications 1997

Mahesparan R, Tysnes BB, Edvardsen K, Haugeland HK, Cabrera IG, Lund-Johansen M, Engebraaten O, Bjerkvig R (1997)
Role of high molecular weight extracellular matrix proteins in glioma cell migration
Neuropathol Appl Neurobiol, 23 (2), 102-12
DOI 10.1046/j.1365-2990.1997.8398083.x, PubMed 9160895

Publications 1996

Maelandsmo GM, Flørenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Børresen AL, Fodstad O (1996)
Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
Br J Cancer, 73 (8), 909-16
DOI 10.1038/bjc.1996.181, PubMed 8611425

Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O (1996)
Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
Cancer Res, 56 (23), 5490-8
PubMed 8968106

Publications 1995

Engebråten O, Kallevåg T, Sørbø HB, Bjugn R (1995)
[Emergency hospital admissions. A survey and consumer assessment of conditions in an emergency department admission office]
Tidsskr Nor Laegeforen, 115 (23), 2917-20
PubMed 7570518

Engebråten O, Sørbø HB, Kallevåg T, Bjugn R (1995)
[Primary health care and emergency admission of patients. What happened prior to admissions and how did the patients experience the primary health care system?]
Tidsskr Nor Laegeforen, 115 (23), 2913-6
PubMed 7570517

Publications 1994

Engebråten O (1994)
[Diagnoses in medical and surgical patients. Experiences of a junior physician]
Tidsskr Nor Laegeforen, 114 (10), 1179-84
PubMed 8209314

Pedersen PH, Ness GO, Engebraaten O, Bjerkvig R, Lillehaug JR, Laerum OD (1994)
Heterogeneous response to the growth factors [EGF, PDGF (bb), TGF-alpha, bFGF, IL-2] on glioma spheroid growth, migration and invasion
Int J Cancer, 56 (2), 255-61
DOI 10.1002/ijc.2910560219, PubMed 8314309

Pedersen PH, Rucklidge GJ, Mørk SJ, Terzis AJ, Engebraaten O, Lund-Johansen M, Backlund EO, Laerum OD, Bjerkvig R (1994)
Leptomeningeal tissue: a barrier against brain tumor cell invasion
J Natl Cancer Inst, 86 (21), 1593-9
DOI 10.1093/jnci/86.21.1593, PubMed 7932823

Wester K, Bjerkvig R, Cressey L, Engebraaten O, Mørk S (1994)
Organ culture of a glioblastoma from a patient with an unusually long survival
Neurosurgery, 35 (3), 428-32; discussion 432-3
DOI 10.1227/00006123-199409000-00010, PubMed 7800134

Publications 1993

Engebråten O (1993)
[Hypoplastic left heart syndrome]
Tidsskr Nor Laegeforen, 113 (30), 3770-1
PubMed 8278970

Engebraaten O, Bjerkvig R, Pedersen PH, Laerum OD (1993)
Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro
Int J Cancer, 53 (2), 209-14
DOI 10.1002/ijc.2910530206, PubMed 8381111

Publications 1992

Engebråten O (1992)
Biology and experimental therapy of invasive glioma cellsin tissue culture: with emphasis on membrane related structures
The Gade Institute, Department of Pathology, University of Bergen, Bergen, 1 b.(flere pag.)
BIBSYS 931753201, ISBN 82-91304-01-7

Engebraaten O, Schwachenwald R, Valen H, Bjerkvig R, Laerum OD, Backlund EO (1992)
Effects of high and low single dose irradiation on glioma spheroid invasion into normal rat brain tissue in vitro
Anticancer Res, 12 (5), 1501-6
PubMed 1444212

Lehmann AK, Bjugn R, Engebråten O, Hexeberg E (1992)
[Working conditions of medical students--medical students and research]
Tidsskr Nor Laegeforen, 112 (17), 2202-4
PubMed 1523657

Lehmann AK, Hexeberg E, Engebråten O, Bjugn R (1992)
[Research interest and recruitment potential--medical students and research]
Tidsskr Nor Laegeforen, 112 (17), 2205-7
PubMed 1523658

Publications 1991

Bjerkvig R, Engebraaten O, Laerum OD, Fredman P, Svennerholm L, Vrionis FD, Wikstrand CJ, Bigner DD (1991)
Anti-GM2 monoclonal antibodies induce necrosis in GM2-rich cultures of a human glioma cell line
Cancer Res, 51 (17), 4643-8
PubMed 1873810

Engebraaten O, Bjerkvig R, Berens ME (1991)
Effect of alkyl-lysophospholipid on glioblastoma cell invasion into fetal rat brain tissue in vitro
Cancer Res, 51 (6), 1713-9
PubMed 1998962

Publications 1990

Engebraaten O, Bjerkvig R, Lund-Johansen M, Wester K, Pedersen PH, Mørk S, Backlund EO, Laerum OD (1990)
Interaction between human brain tumour biopsies and fetal rat brain tissue in vitro
Acta Neuropathol, 81 (2), 130-40
DOI 10.1007/BF00334501, PubMed 2082653

Lund-Johansen M, Engebraaten O, Bjerkvig R, Laerum OD (1990)
Invasive glioma cells in tissue culture
Anticancer Res, 10 (5A), 1135-51
PubMed 2241095